IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.047
EU - Europa 3.835
AS - Asia 3.818
SA - Sud America 402
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 14.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.933
SG - Singapore 1.449
CN - Cina 1.135
IT - Italia 599
UA - Ucraina 531
IE - Irlanda 508
GB - Regno Unito 438
RU - Federazione Russa 398
TR - Turchia 369
SE - Svezia 368
VN - Vietnam 362
FR - Francia 339
BR - Brasile 334
DE - Germania 235
FI - Finlandia 141
IN - India 134
PL - Polonia 127
BD - Bangladesh 87
HK - Hong Kong 76
CA - Canada 58
MX - Messico 44
ES - Italia 33
JP - Giappone 33
ZA - Sudafrica 31
AR - Argentina 30
SA - Arabia Saudita 28
CZ - Repubblica Ceca 27
BE - Belgio 23
IQ - Iraq 21
KR - Corea 19
ID - Indonesia 18
NL - Olanda 18
AT - Austria 15
LT - Lituania 12
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
UZ - Uzbekistan 10
IR - Iran 9
MA - Marocco 9
CL - Cile 7
EC - Ecuador 7
AU - Australia 6
CO - Colombia 6
PH - Filippine 6
VE - Venezuela 6
BY - Bielorussia 5
EU - Europa 5
JO - Giordania 5
LY - Libia 5
MY - Malesia 5
AZ - Azerbaigian 4
DZ - Algeria 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
PS - Palestinian Territory 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
CH - Svizzera 3
GR - Grecia 3
IL - Israele 3
KZ - Kazakistan 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
UY - Uruguay 3
BN - Brunei Darussalam 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
LB - Libano 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
GY - Guiana 1
HR - Croazia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SN - Senegal 1
TO - Tonga 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 14.184
Salva come PNG Salva come JPEG
Città #
Singapore 1.071
San Jose 748
Chandler 662
Jacksonville 583
Dublin 499
Ashburn 417
Dallas 343
Southend 312
Beijing 285
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Council Bluffs 152
Los Angeles 150
Ho Chi Minh City 115
Wilmington 101
Kraków 98
Cambridge 96
New York 91
Hanoi 90
Chieti 89
Tongling 84
Santa Clara 80
Altamura 79
Hong Kong 71
The Dalles 71
Ann Arbor 67
Nanchang 64
Boardman 55
Buffalo 52
Munich 50
Moscow 44
Shenyang 42
São Paulo 39
Woodbridge 38
Redondo Beach 34
Changsha 29
Hebei 29
Pescara 29
Tianjin 29
Denver 28
Hefei 28
Orem 28
Rome 28
Atlanta 27
Grevenbroich 27
Helsinki 27
Warsaw 27
Jiaxing 25
Chicago 24
Montreal 24
Riyadh 23
Seattle 23
Tokyo 23
Washington 23
Brno 22
Houston 22
Brooklyn 21
Kocaeli 21
Brussels 20
Hangzhou 20
Johannesburg 20
Kunming 20
Camerino 19
Phoenix 18
Seoul 18
Shanghai 18
St Louis 18
Mexico City 17
Orange 17
Toronto 17
Norwalk 16
Spoltore 16
Da Nang 15
Manchester 15
Nuremberg 15
Poplar 15
Lappeenranta 14
Stockholm 14
Boston 13
Chennai 13
Jinan 13
Mumbai 13
Ankara 12
Belo Horizonte 12
Düsseldorf 12
Haiphong 12
Milan 12
Frankfurt am Main 11
Guangzhou 11
Leawood 11
Rio de Janeiro 11
San Francisco 11
Lanzhou 10
London 10
Amsterdam 9
Dong Ket 9
Hải Dương 9
Murcia 9
Totale 8.651
Salva come PNG Salva come JPEG
Nome #
Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease 425
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 245
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 184
Antithrombotic Agents and Cancer 182
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 172
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 167
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 164
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 157
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 156
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 155
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 155
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 152
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 150
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 149
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 149
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 148
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 145
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 144
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 142
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 137
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 136
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 135
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 134
New insights into COX-2 biology and inhibition. 133
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 132
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 131
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 130
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 129
Clinical pharmacology of selective COX-2 inhibitors. 129
Oxidative stress and platelet activation in essential hyperytension 128
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 127
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 127
Determinants of platelet activation in human essential hypertension. 127
Platelet activation in patients with colorectal cancer. 126
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 124
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 124
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 123
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 123
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 122
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 122
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 122
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 121
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 121
Gut microbiota, host gene expression, and aging. 121
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 121
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 120
Risk management profile of etoricoxib: An example of personalized medicine 120
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 119
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 119
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 119
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 119
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 118
Clinical pharmacology of novel selective COX-2 inhibitors. 118
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 118
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 118
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 117
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 117
Mechanistic and pharmacological issues of aspirin as an anticancer agent 117
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 116
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 116
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 116
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 116
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 115
NSAIDs and cardiovascular disease. 115
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 114
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 114
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 113
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A2 receptor 112
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 112
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 112
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 111
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 110
Clinical pharmacology of etoricoxib. 109
Pharmacodynamic of cyclooxygenase inhibitors in humans. 108
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 108
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 107
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 106
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 106
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 106
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 104
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 103
Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro 103
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 102
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 102
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 100
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 99
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 99
P2Y12 Receptors in Tumorigenesis and Metastasis 99
Cyclooxygenases and platelet functions 98
Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention 98
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 96
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 96
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 96
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 95
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 93
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 93
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 93
Evaluating plasma vesicle signatures in chronic coronary artery disease patients for tailored dual therapy with low-dose rivaroxaban and aspirin 92
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 92
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 92
Totale 12.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 0 0 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/20265.613 443 250 526 672 471 307 829 328 558 430 315 484
Totale 14.655